Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer
Hyo Song Kim(Yonsei University), Sun Young Rha(Yonsei University), Sang Kil Lee(Korea Advanced Institute of Science and Technology), Song‐Ee Baek(Yonsei University), Woo Jin Hyung(Sechenov University), Minkyu Jung(Cancer Research Institute), Hyunki Kim(Yonsei University), Taeil Son(The Catholic University of Korea Seoul St. Mary's Hospital), Seung‐Hoon Beom(Yonsei University), Joon Seok Lim(Yonsei University), Sung Hoon Noh(Gangnam Severance Hospital), Woong Sub Koom(Yonsei University), Sung Kwan Shin(Yonsei University), Beodeul Kang(CHA University Bundang Medical Center), Jee Suk Chang(Yonsei University), Inkyung Jung(Korea Advanced Institute of Science and Technology), Yong Chan Lee(Yonsei University), Su‐Jin Shin(Yonsei University), Yoon Young Choi(Yonsei University), Hyun Cheol Chung(Yonsei University), Hyunsoo Chung(Seoul National University), Eun Hye Kim(Sungkyunkwan University), Jae‐Ho Cheong(Yonsei University), Hyoung‐Il Kim(Yonsei University), Jun Chul Park(Yonsei University)
Cited by 8
Related Papers
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
|Journal of Clinical Oncology|2016|859